Recent Updates — ELOXD

Eloxx Pharmaceuticals reported second quarter 2026 financial results and announced the completion of an underwritten public offering that raised $66.0 million in gross proceeds ($58.3 million net) from selling 2,975,000 shares at $11.00 per share. The company also completed its uplisting to the Nasdaq Capital Market and holds $62.0 million in cash with no debt as of June 30, 2026. Management plans to initiate a Phase 2b clinical trial for exaluren in nonsense mutation Alport syndrome in Q3 2026 and a Phase 2 trial for ADPKD in 2027. The company incurred a net loss of $4.5 million ($0.39 per share) for the quarter, with R&D expenses rising to $2.8 million due to increased clinical trial activity. Additionally, the European Commission granted orphan designation for exaluren in ADPKD, and two new directors were appointed to the board.